Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Bacteria Discovered to Break Down Chemotherapy Drugs

Bacteria Discovered to Break Down Chemotherapy Drugs

One of the most important problems encountered in cancer treatment is resistance to chemotherapy drugs. In recent years, various factors causing drug resistance in cancer have been investigated. In September 2017, Science published a study showing that bacteria inside pancreatic cancer cells inactivate one of the few chemotherapy drugs shown to work in this cancer, gemcitabine , by breaking it down.

The study discovered that a bacterium called M. hyorhinis is present inside cancer cells and breaks down the drug gemcitabine. To do this, the bacterium uses an enzyme called cytidine deaminase (cytidine deaminase).

  • Researchers then examined whether this enzyme was also present in other bacterial species. Among 2674 bacteria that can live in humans, the enzyme was identified in 11 percent.
  • 113 pancreatic cancer patients provided tissue samples that were investigated for these bacteria. Bacteria producing the enzyme that breaks down gemcitabine were identified in 86 patients. These bacterial types generally include species such as E. coli and salmonella.
  • In addition, these types of bacteria were injected into laboratory animals to understand the role of bacteria in tumor resistance to drugs. In mice given gemcitabine and an antibiotic, the bacteria were effectively eliminated and the tumor shrank. In mice given gemcitabine alone, the tumor grew rapidly.

So What Does This Study Mean for Us?

  • An important mechanism of drug resistance has been clarified. In cancer, drug resistance is caused not only by the tumor microenvironment but also by bacteria within the cancer’s internal structure.
  • This study may explain why gemcitabine ceases to be effective after some time on treatment in most patients with pancreatic cancer.
  • In the future, cancer treatments may be planned according to the bacteria a patient carries.
  • This study was conducted in laboratory cell cultures and animal models. It needs to be confirmed by further studies in humans.
  • Further studies may also investigate antibiotic use alongside standard cancer treatments. However, it must be emphasized that long-term antibiotic use may cause antibiotic-resistant bacteria to emerge and also reduces the effectiveness of cancer immunotherapies .
  • Developing drugs that inhibit the activity of the enzymes enabling bacteria to break down the drug is a better solution. In that case, antibiotics would not be needed and the bacteria would not develop resistance.
  • The same research group is analyzing how another chemotherapy drug, oxaliplatin, is broken down by bacteria.

Article Image: Bacteria (shown in green) are visible inside pancreatic cancer cells.

Sources

Leore T. Geller, Michal Barzily-Rokni, Tal Danino ve ark.
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Science - 15 Sep 2017

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Bacteria Discovered to Break Down Chemotherapy Drugs

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy